Scribe Therapeutics secures $25m to advance CRISPR therapies

Scribe Therapeutics has been awarded more than $25 million by the California Institute for Regenerative Medicine to advance two preclinical CRISPR-based gene editing programs, STX-1200 and STX-1400, toward clinical trials. STX-1200 targets LPA to lower lipoprotein(a) in patients with genetically ele…

View Post on Scour ↗

More from longevity.technology on Scour.